Pyxis Oncology, Inc. PYXS

2.86 (0.06) (2.05%) as of 25 Sep
Market cap
$250.2M
P/E
0.0×
Dec '17 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
— — — — — — 0.00 0.00
P/S ratio
— — — — — — 0.00 0.00
P/FCF ratio
— — — — — — 0.00 0.00
P/Operating CF
— — — — — — (4.73) (6.85)
P/B ratio
— — — — — — 0.76 1.34
Price to Tangible BV
— — — — — — 0.77 1.40
EV/Sales
— — — — — — 0.00 0.00
EV/EBITDA
— — — — — — 0.40 0.00
EV/Operating CF
— — — — — — 0.65 (0.05)
EV/FCF
— — — — — — 0.64 (0.05)
Quick Ratio
— 26.86 2.19 14.76 5.71 4.69 7.26 3.23
Current Ratio
— 26.88 2.20 14.90 5.90 4.84 7.49 3.41
Net Debt/EBITDA
— 6.83 0.65 4.00 1.47 1.42 1.39 0.82
Debt/Assets
0.00% 0.08% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
— 0.00 0.00 0.00 0.00 0.00 0.10 0.11
Operating CF/Net income
— 0.81 0.79 0.47 0.74 0.96 0.75 0.80
Capex/Depreciation
— — (3.16) (0.83) (9.03) 2.35 0.08 (0.01)
Interest Coverage
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE
— 29.94% 138.54% (61.85%) (57.19%) (51.51%) (62.75%) (91.43%)
ROA
— (27.99%) (85.64%) (52.37%) (49.13%) (38.32%) (46.74%) (64.03%)
ROIC
— 0.00% 0.00% 0.00% 0.00% (1,041.19%) 0.00% 0.00%
Return on Tangible Assets
— (14.56%) (232.52%) (29.11%) (72.66%) (66.65%) (62.03%) (135.02%)
Average Days of Receivables
— — — — 0.00 — 0.00 0.00
Research and Development Expense of Revenue
— 0.00% 0.00% 0.00% 0.00% 0.00% 363.85% 531.79%
Selling, General and Administrative Expense of Revenue
— 0.00% 0.00% 0.00% 0.00% 0.00% 157.44% 160.15%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.14 0.02 0.00
Share Based Compensation of Revenue
— — 0.00% 0.00% 0.00% 0.00% 80.17% 85.16%
Graham Net Nets
— — — — — — 1.05 0.48
Graham Number
— — — — — — 0.00 0.00
Earnings Yield
— — — — — — (83.33%) (112.17%)
Free Cash Flow Yield
— — — — — — (63.51%) (88.87%)
Revenue per Share
— 0.00 0.00 0.00 0.00 0.00 0.28 0.22
Operating CF per Share
— (0.07) (9.78) (4.16) (2.70) (1.77) (0.99) (1.02)
Capex per Share
— 0.00 (1.44) (0.06) (0.19) (0.17) 0.00 0.00
Free Cash Flow per Share
— (0.07) (11.22) (4.22) (2.90) (1.94) (0.99) (1.02)
Cash per Share
— 0.57 7.84 32.52 5.47 3.03 2.20 1.10
Shareholders Equity per Share
— 0.56 (15.17) 30.77 4.87 3.15 2.07 0.86
Interest Debt per Share
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
— 0.56 (15.17) 30.77 4.87 3.15 2.07 0.86
Free Cash Flow
— (2.24) (11.57) (35.87) (95.73) (77.43) (57.91) (63.51)
Working Capital
— 18.97 4.41 259.97 154.98 98.85 114.76 50.97
Capital Expenditures
— — (1.48) (0.54) (6.40) (6.73) (0.24) (0.01)
Net Current Asset Value
— 18.96 (17.69) 259.97 136.06 76.58 96.01 33.99
EV/EBIT
— — — — — — 0.42 0.00
Capex to Sales
— — 0.00 0.00 0.00 0.00 0.01 0.00
Net Profit Margin
— 0.00% 0.00% 0.00% 0.00% 0.00% (478.95%) (574.55%)
Price to Operating Income
— — — — — — 0.00 0.00
Other line items
Depreciation/Fixed assets
— 0.00 0.43 0.64 0.06 (0.24) (0.32) 0.19
Cash ROIC
— (5.97%) 147.88% (6.76%) (29.42%) (33.50%) (27.12%) (58.73%)
Accounts Receivable Turnover
— — — — — — 0.00 0.00
Accounts Payable Turnover
— 0.00 0.57 0.19 0.19 0.00 0.11 0.30
Inventory Turnover
— — 0.00 0.00 0.00 — 0.00 0.00
Average Days of Payables
— 0.00 885.37 3,486.90 1,410.90 0.00 3,733.76 1,663.75
Days of Inventory on Hand
— — 0.00 0.00 0.00 — 0.00 0.00
Average Payables
— 0.78 0.78 6.51 9.52 5.50 4.38 7.87
Average Assets
— 9.90 14.98 145.09 245.70 192.55 165.45 124.35
Average Common Equity
— (9.26) (9.26) 122.83 211.07 143.26 123.23 87.08

Fold the line items

Columns are period end dates